Skip to main content

Advertisement

Log in

Theoretical Considerations of Target-Mediated Drug Disposition Models: Simplifications and Approximations

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Purpose

To clarify relationships among various types of target-mediated disposition (TMD) models including the Michaelis-Menten, quasi-steady-state (Qss), and rapid binding models and propose measures for the closeness of some models as approximations to the general TMD model (Mager and Jusko, J Pharmacokinet Pharmacodyn 28(6):507–532, 2001).

Methods

Based on the classic singular perturbation theory by selecting appropriate scales of time, we derive requirements with which the Michaelis-Menten and Qss models are suitable approximations. Under the Qss assumption we show that other simplifications of the general TMD model can be similarly obtained as the Michaelis-Menten and Qss models. We compare these models by simulations using known application examples.

Results

The Michaelis-Menten and Qss models are direct simplifications of the general TMD model and, moreover, suitable approximations if certain specific requirements on the parameters are met.

Conclusions

As a first attempt to quantify the closeness of some simplifications to the general TMD model, our work should provide a more rigorous basis for the theoretical and practical research of TMD models, which are important for investigating the pharmacokinetic-pharmacodynamic relationships of many biological compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

REFERENCES

  1. Mager D, Jusko W. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32.

    Article  PubMed  CAS  Google Scholar 

  2. Woo S, Krzyzanski W, Jusko W. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn. 2007;34:849–68.

    Article  PubMed  CAS  Google Scholar 

  3. Krzyzanski W, Wiczling P, Lowe P, Pigeolet E, Fink M, Berghout A, et al. Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations. J Clin Pharmacol. 2010;50(9 suppl):101S–12S.

    Article  PubMed  CAS  Google Scholar 

  4. Jin F, Krzyzanski W. Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci. 2004;6(1) Article 9.

  5. Mager D, Jusko W. Receptor-mediated pharmacokinetic pharmacodynamic model of interferon-β 1a in humans. Pharm Res. 2002;19(10):1537–43.

    Article  PubMed  CAS  Google Scholar 

  6. Eppler S, Combs D, Henry T, Lopez J, Ellis S, Yi JH, et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther. 2002;72(1):20–32.

    Article  PubMed  CAS  Google Scholar 

  7. Dirks N, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633–59.

    Article  PubMed  CAS  Google Scholar 

  8. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56:248–52.

    Article  PubMed  CAS  Google Scholar 

  9. Hayashi N, Tsukamoto Y, Sallas W, Lowe P. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63(5):548–61.

    Article  PubMed  CAS  Google Scholar 

  10. Bauer R, Dedrick R, White M, Murray M, Garovoy M. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Pharmacodyn. 1999;27(4):397–420.

    CAS  Google Scholar 

  11. Gibiansky L, Gibiansky E. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic and pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol. 2009;5(7):803–12.

    Article  PubMed  CAS  Google Scholar 

  12. Mager D, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589–96.

    Article  PubMed  CAS  Google Scholar 

  13. Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2009;35:573–91.

    Article  Google Scholar 

  14. Peletier L, Gabrielsson J. Dynamics of target-mediated drug disposition. European J Pharm Sci. 2009;38:445–64.

    Article  CAS  Google Scholar 

  15. Jonsson E, Macintyre F, James I, Krams M, Marshall S. Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition. Pharm Res. 2005;22:1236–46.

    Article  PubMed  CAS  Google Scholar 

  16. Klonowski W. Simplifying principles for chemical and enzyme reaction kinetics. Biophy Chem. 1983;18:73–83.

    Article  CAS  Google Scholar 

  17. Segel L, Slemrods M. The quasi-steady-state assumption: a case study in perturbation. SIAM Rev. 1989;31(3):446–77.

    Article  Google Scholar 

  18. Segel I. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York: Wiley; 1975.

    Google Scholar 

  19. Yan X, Mager D, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2010;37:25–47.

    Article  PubMed  CAS  Google Scholar 

  20. Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58.

    Article  PubMed  CAS  Google Scholar 

  21. van Bueren JJ Lammerts, Bleeker WK, Bøgh HO, Houtkamp M, Schuurman J, van de Winkel JGJ, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 2006;66(15):7630–8.

    Article  Google Scholar 

  22. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria; 2010. ISBN 3-900051-07-0. Available from: http://www.R-project.org.

  23. Setzer RW. odesolve: Solvers for ordinary differential equations; 2008. R package version 0.5-20.

  24. Ng C, Stefanich E, Anand B, Fielder P, Vaickus L. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res. 2006;23(1):95–103.

    Article  PubMed  CAS  Google Scholar 

  25. Marathe A, Peterson M, Mager D. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther. 2008;326:555–62.

    Article  PubMed  CAS  Google Scholar 

  26. Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin SL, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res. 2011;19(10):1537–43.

    Google Scholar 

  27. Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson M, et al. Population pharmacokinetic analysis of denosumab in advanced cancer patients with solid tumors. In: American Conference of Pharmacometrics. San Diego, CA; 2011.

  28. Gibiansky L, Gibiansky E. Irreversible binding (IB) and Michaelis-Menten (MM) approximations of the target-mediated drug disposition (TMDD) model. In: AAPS National Biotechnology Conference. San Francisco, CA; 2010.

  29. Marathe A, Krzyzanski W, Mager D. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn. 2009;36:199–219.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS & DISCLOSURES

I thank Ms. Florence Hourcade-Potelleret for helpful discussions, and I also thank the reviewers for insightful comments.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peiming Ma.

APPENDIX

APPENDIX

The one-compartment Michaelis-Menten model with a bolus injection and constant total target is a particularly illustrative case for a simplification of the general TMD model under the Qss assumption. We provide here more details of the free drug C that can be expressed using a special mathematical function and the complex M that can be improved over the usual choice. We recommend the use of the improved expression of M (Eq. 46) in modeling.

Inner and Outer Layers

From the terminology of singular perturbation theory, the free drug C (≈ C 0) and complex M given in (29) as a solution to (28) are valid at the initial fast binding time and called the inner layer, but the solution of C and M to (30) and (31) are valid at the later quasi-steady state and called the outer layer. If k e > 0, Eq. 30 for the outer layer can be transformed to a (transcendental) equation after integration

$$ \frac{C}{{{K_{\text{m}}}}}{\left( {1 + \frac{{{k_{\text{e}}}}}{{{k_{\text{e}}} + {k_{\text{n}}}}}\frac{C}{{{K_{\text{m}}}}}} \right)^{{{k_{\text{n}}}/{k_{\text{e}}}}}} = {G_0}{e^{{ - ({k_{\text{e}}} + {k_{\text{n}}})t}}}, $$
(45)

where \( {k_{\text{n}}} = {V_{{\max }}}/{K_{\text{m}}} \) and \( {V_{{\max }}} = {k_{\text{met}}}{R_{\text{tot}}} \). The parameter k n is the maximum nonlinear elimination rate constant for the free drug in the Michaelis-Menten model. The constant \( {G_0} = {G_0}\left( {{C_0}/{K_{\text{m}}},\;{k_{\text{n}}}/{k_{\text{e}}}} \right) \) is equal to the left-hand side of the above equation at t = 0 and thus dependent on C 0/K m and k n/k e. If k e = 0, then V max > 0 (see the assumption of nontrivial TMD models in “Methods”), and the integration of (30) results in the limit of the above equation as k e → 0:

$$ \left( {C/{K_{\text{m}}}} \right){e^{{C/{K_{\text{m}}}}}} = {G_0}{e^{{ - {k_{\text{n}}}t}}}. $$

Thus, C is equal to \( {K_{\text{m}}}W\left( {{G_0}{e^{{ - {k_{\text{n}}}t}}}} \right) \) at k e = 0, where W is the Lambert W-function (or omega function), which is the inverse of f (x) = xex. As a generalization of W, if we denote W(x; α) as the inverse of \( f\left( {x;\alpha } \right) = x{\left( {1 + \alpha x} \right)^{{1/\alpha }}} \) then the free drug concentration C in (45) is approximately \( {K_{\text{m}}}W\left( {{G_0}{e^{{\left( { - {k_{\text{e}}} + {k_{\text{n}}}} \right)t}}};\;{k_{\text{e}}}/\left( {{k_{\text{e}}} + {k_{\text{n}}}} \right)} \right) \) for small k e.

Note that a consequence of making the Qss assumption is M (0) = M 0 ≠ 0 if M is the outer layer and given by the first formula in (13), but the limit of the outer layer as t → 0 is the same as the inner layer in (29) as t → ∞. Thus, an improvement to both inner and outer layers as approximations of the complex can be made. With a standard matching technique, a total solution for M can be proposed as the sum of the inner and outer layers minus the overlapping term, which gives

$$ M = {R_{\text{tot}}}\left[ {\frac{C}{{{K_{\text{m}}} + C}} - \frac{{{C_0}}}{{{K_{\text{m}}} + {C_0}}}\exp ( - {k_{\text{on}}}({K_{\text{m}}} + {C_0})t)} \right], $$
(46)

where C is given in (45). Simulation examples in Figs. 5 and 6 show that the improvement corrects the over-estimation of the complex at initial time. In all cases, for small t the improved complex M overlaps completely with that of the general TMD model (plots not shown).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ma, P. Theoretical Considerations of Target-Mediated Drug Disposition Models: Simplifications and Approximations. Pharm Res 29, 866–882 (2012). https://doi.org/10.1007/s11095-011-0615-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-011-0615-2

KEY WORDS

Navigation